Pathophysiology of Sickle Cell Disease and New Drugs for the Treatment
2009
Pathophysiology of Sickle Cell Disease and New Drugs for Treatment
publication
Author Information
Author(s): Lucia De Franceschi
Primary Institution: University of Verona, Italy
Hypothesis
The study explores the biochemical properties of sickle hemoglobin and potential therapeutic strategies for sickle cell disease.
Conclusion
New pharmacological targets for treating sickle cell disease include agents that prevent dehydration of sickle cells and reduce their adhesion to endothelial cells.
Supporting Evidence
- Hydroxycarbamide is the only drug currently approved for chronic use in sickle cell disease.
- Long-term use of hydroxycarbamide has shown significant reductions in mortality and morbidity.
- New therapeutic strategies include agents that prevent sickle cell dehydration and reduce sickle cell-endothelial adhesion.
Takeaway
Sickle cell disease happens because of a problem with hemoglobin, and scientists are looking for new ways to treat it by stopping sickle cells from getting dehydrated and sticking to blood vessels.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website